Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?
| العنوان: | Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events? |
|---|---|
| المؤلفون: | Paolo Calabresi, Letizia M. Cupini, Chiara Bedetti, Paola Sarchielli, Cinzia Costa, Sabrina Siliquini, Ilenia Corbelli, Michele Romoli, Stefano Caproni, Paolo Eusebi |
| المصدر: | Cephalalgia. 38:274-282 |
| بيانات النشر: | SAGE Publications, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Male, Pediatrics, medicine.medical_specialty, Adolescent, Migraine Disorders, Lamotrigine, neuropharmacology, Young Adult, 03 medical and health sciences, Epilepsy, 0302 clinical medicine, Topiramate, medicine, Humans, migraine, antiepileptic drugs, 030212 general & internal medicine, Child, Adverse effect, Tolerability, adverse events, epilepsy, Neuropharmacology, Aged, Aged, 80 and over, business.industry, Valproic Acid, General Medicine, Middle Aged, medicine.disease, Settore MED/26 - NEUROLOGIA, Increased risk, Migraine, Anesthesia, Anticonvulsants, Female, Neurology (clinical), business, 030217 neurology & neurosurgery |
| الوصف: | Background The impact of adverse events (AEs) of antiepileptic drugs (AEDs) have an impact on compliance and dropouts. We compared tolerability of AEs of AEDs among patients with migraine, epilepsy, or both. Methods Overall, 335 patients (epilepsy (n = 142), migraine (n = 131), and both (n = 62)), were evaluated with the Liverpool Adverse Events Profile (LAEP) to assess the magnitude, profile and occurrence rate of the AEs of valproate, topiramate, and lamotrigine. Results AEs were significantly more common with topiramate treatment (71.0%) and among migraineurs (69.5%), the latter being more prone to discontinue AEDs (46.6%). The profile of AEs with topiramate and valproate differed among groups. Moreover, treatment with both topiramate and valproate was associated, for all groups, with a worse tolerability profile compared to lamotrigine. Conclusion Our data suggest a specific drug and disease AE profile of AEDs. Specifically, migraineurs are the most affected by AEs, even though they receive very low dosages of AEDs. This finding might be considered a clinical implication of central sensitization mechanisms. Both the profile and tolerability of AEs, highly influencing quality of life, depended on the underlying conditions, and deeply impacted on treatment dropout. Therefore, before starting, switching or stopping AED treatment, all options need to be considered. |
| تدمد: | 1468-2982 0333-1024 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96fe833894515203592d71dd302fb9dfTest https://doi.org/10.1177/0333102416683925Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....96fe833894515203592d71dd302fb9df |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14682982 03331024 |
|---|